Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Stemline Therapeutic (STML)

Stemline Therapeutic (STML)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Stemline Therapeutic 750 LEXINGTON AVENUE ELEVENTH FLOOR NEW YORK NY 10022 USA

www.stemline.com P: 646-502-2311

Description:

Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York.

Key Statistics

Overview:

Market Capitalization, $K 621,205
Shares Outstanding, K 52,511
Annual Sales, $ 43,220 K
Annual Net Income, $ -76,820 K
Last Quarter Sales, $ 8,870 K
Last Quarter Net Income, $ -21,290 K
60-Month Beta 1.78
% of Insider Shareholders 11.20%
% of Institutional Shareholders 75.80%
Float, K 46,630
% Float 88.80%

Growth:

1-Year Return -18.30%
3-Year Return 42.53%
5-Year Return -6.04%
5-Year Revenue Growth 12,996.97%
5-Year Earnings Growth 17.94%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 06/05/20
Earnings Per Share ttm -1.59
EPS Growth vs. Prev Qtr -18.42%
EPS Growth vs. Prev Year 38.36%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

STML Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -48.14%
Return-on-Assets % -41.35%
Profit Margin % -177.74%
Debt/Equity 0.00
Price/Sales 14.58
Price/Cash Flow N/A
Price/Book 4.20
Book Value/Share 2.81
Interest Coverage -2,558.67
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar